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ABSTRACT Sharp-1, a basic helix-loop-helix transcription factor, is a potent repressor of skel-
etal muscle differentiation and is dysregulated in muscle pathologies. However, the mecha-
nisms by which it inhibits myogenesis are not fully understood. Here we show that G9a, a 
lysine methyltransferase, is involved in Sharp-1–mediated inhibition of muscle differentiation. 
We demonstrate that G9a directly interacts with Sharp-1 and enhances its ability to transcrip-
tionally repress the myogenin promoter. Concomitant with a differentiation block, G9a-de-
pendent histone H3 lysine 9 dimethylation (H3K9me2) and MyoD methylation are apparent 
upon Sharp-1 overexpression in muscle cells. RNA interference–mediated reduction of G9a 
or pharmacological inhibition of its activity erases these repressive marks and rescues the 
differentiation defect imposed by Sharp-1. Our findings provide new insights into Sharp-1–
dependent regulation of myogenesis and identify epigenetic mechanisms that could be tar-
geted in myopathies characterized by elevated Sharp-1 levels.
INTRODUCTION
Myogenic regulatory factors (MRFs) MyoD, Myf5, myogenin, and 
MRF4 act together with epigenetic regulatory mechanisms to con-
trol skeletal muscle differentiation. All MRFs heterodimerize with 
ubiquitously expressed E-proteins (E12, E47) and bind to E-box se-
quences (CANNTG) in target gene promoters, thereby driving tran-
scription of muscle-specific genes. MyoD and Myf5 are expressed 
in undifferentiated proliferating myoblasts. During differentiation, 
MyoD is activated and induces an irreversible cell cycle arrest by 
up-regulation of p21Cip/WAF1 expression, as well as activation of myo-
genin and MEF2, which are required for differentiation (Sabourin 
and Rudnicki, 2000; Sartorelli and Caretti, 2005; Tapscott, 2005). 
Because MyoD is expressed in myoblasts, its ability to induce cell 
cycle arrest and differentiation is tightly controlled by several mech-
anisms. For instance, high levels of Id in myoblasts sequester 
E-proteins, resulting in a block of MyoD transcriptional activity. Many 
DNA-binding transcription factors, including Hes1, Sharp-1, Mist, 
MyoR, and Twist, negatively affect MyoD function by competition 
for binding to E-box sites, formation of inactive heterodimers, 
and inhibition of its transcriptional activity. In addition, chromatin-
modifying enzymes HDAC1, Ezh2, Suv39h1, and G9a, which are 
expressed in myoblasts, mediate repressive histone deacetylation 
and methylation marks on early and late muscle promoters, preclud-
ing MyoD transcriptional activity (Puri and Sartorelli, 2000; McKinsey 
et al., 2001; Perdiguero et al., 2009; Bharathy and Taneja, 2012). 
Among these, G9a mediates transcriptional repression by mono-
methylation and dimethylation of histone H3 lysine-9 (H3K9; Shinkai 
and Tachibana, 2011) and also methylates MyoD at Lys-104 (K104; 
Ling et al., 2012). Although increasing evidence demonstrates that 
repressive epigenetic modifications of histone and nonhistone sub-
strates are important in the maintenance of an undifferentiated state 
of muscle cells, the mechanisms by which corepressors are recruited 
to muscle-specific promoters in myoblasts are largely unclear.
Sharp-1 is expressed widely in a number of cell types, including 
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promoter reporter pMyog-Luc (Friday et al., 2000). Consistent with 
previous reports, MyoD-induced reporter activity was inhibited by 
Sharp-1 and G9a individually (Azmi et al., 2004; Ling et al., 2012). 
Coexpression of G9a enhanced Sharp-1–dependent repression of 
the myogenin promoter (Figure 1H), whereas treatment with BIX-
01294 or UNC0638 abrogated it (Figure 1I). Moreover, G9a∆ANK 
did not enhance Sharp-1–dependent repression of the myogenin 
promoter, and Sharp-1 basic helix-loop-helix (bHLH)–dependent re-
pression was not increased by G9a (Figure 1J). To further assess 
whether G9a is expressed in vivo in muscle cells, we analyzed its 
expression in mouse embryos at embryonic day 12 (E12) to E16 by 
immunohistochemistry. G9a was widely expressed at all stages, and 
its expression was apparent in developing skeletal muscles, includ-
ing diaphragm, limb, and tongue (Figure 1K). We and others showed 
that Sharp-1 is also expressed in developing tongue and limb mus-
cles in mouse and zebrafish embryos (Azmi and Taneja, 2002; Chen 
et al., 2010), further suggesting a potential regulatory connection 
between the two proteins.
Sharp-1 overexpression correlates with increased H3K9me2 
on the myogenin promoter
We reasoned that if G9a is central to repression of myogenin and 
muscle differentiation by Sharp-1, an increase in its activity should 
be apparent in Sharp-1–overexpressing cells. C2C12 cells were 
transduced with pBabe-Sharp-1 (Sharp-1) or with pBabe vector 
(control; Figure 2A). Consistent with previous reports (Azmi et al., 
2004), Sharp-1 overexpression inhibited myogenic differentiation 
as assessed by reduced number of MHC+ myotubes and myogenic 
index (Figure 2, B and C). Moreover, the levels of myogenin and 
troponin T were strongly down-regulated in Sharp-1–overexpressing 
cells (Figure 2D). We then examined by chromatin immunoprecipita-
tion (ChIP) assays G9a-mediated H3K9me2 on the myogenin pro-
moter. Of interest, a significant increase in H3K9me2 mark was 
apparent in Sharp-1–overexpressing cells (Figure 2E) in a manner 
similar to G9a overexpression (Ling et al., 2012). Correspondingly, 
H3K9K14ac, a mark of transcriptional activation, was reduced upon 
Sharp-1 overexpression (Figure 2F). To further validate these find-
ings, we inhibited endogenous Sharp-1 expression with small inter-
fering RNA (siRNA; siSharp-1). Control cells (siRNA) were transfected 
with scrambled siRNA. Inhibition of endogenous Sharp-1 (Figure 
2G) led to a marked increase in myogenic differentiation and expres-
sion of MyoD target genes (Figure 2, H–J). Moreover, a clear decline 
in H3K9me2 at the myogenin promoter was apparent in siSharp-1 
cells relative to controls (Figure 2K), indicating that G9a is targeted 
to the myogenin promoter in a Sharp-1–dependent manner.
G9a is critical for Sharp-1–mediated repression 
of myogenesis
To test the role of G9a in Sharp-1–dependent inhibition of myogen-
esis, we transfected Sharp-1–overexpressing cells with G9a siRNA 
(siG9a) or as a control, with scrambled siRNA (siRNA). Down-regula-
tion of G9a expression was apparent in siG9a cells relative to con-
trols (Figure 3A). Of interest, siG9a cells exhibited enhanced myo-
tube formation, myogenic index, and myogenic differentiation 
markers compared with siRNA cells (Figure 3, B–D). Moreover, treat-
ment of pBabe-Sharp-1 cells with BIX-01294 rescued myogenic dif-
ferentiation and expression of myogenin and troponin T similar to 
siG9a cells, indicating that G9a methyltransferase activity is essential 
for Sharp-1–mediated block of myogenic differentiation (Figure 3, 
E–G). Concomitant with a rescue of differentiation, H3K9me2 
was reduced on the myogenin promoter in response to BIX-01294 
treatment in Sharp-1–overexpressing cells (Figure 3H). Because 
2002; Azmi et al., 2003), and has complex physiological functions in 
cellular differentiation programs, sleep length, circadian rhythms, 
tumor suppression, and Th2 lineage commitment (Honma et al., 
2002; Azmi et al., 2004; Rossner et al., 2008; Gulbagci et al., 2009; 
Yang et al., 2009a; He et al., 2009). We previously demonstrated 
that Sharp-1 interacts with MyoD, resulting in the inhibition of its 
transcriptional activity and muscle differentiation (Azmi et al., 2004). 
Consistent with these findings, Sharp-1 is overexpressed in inclusion 
body myositis, which exhibits a differentiation defect, and is also 
associated with loss of skeletal muscle mass (Morosetti et al., 2006; 
Lecomte et al., 2010). Despite growing evidence of deregulated ex-
pression in pathologies, the mechanisms by which Sharp-1 functions 
as a repressor of differentiation have not been elucidated.
Here we identify G9a as a corepressor that mediates Sharp-1–
dependent block of skeletal myogenesis. Sharp-1 and G9a physi-
cally associate, and inhibition of differentiation by Sharp-1 correlates 
with increased G9a-dependent H3K9me2 at the myogenin pro-
moter, as well as with MyoD methylation. RNA interference–medi-
ated reduction of G9a or inhibition of its activity in Sharp-1–overex-
pressing cells restores differentiation concomitant with removal of 
repressive methylation marks. Reexpression of wild-type MyoD and 
MyoD(K104R), where Lys-104 is mutated to arginine, underscores a 
role for G9a-dependent MyoD methylation in Sharp-1–dependent 
inhibition of myogenesis.
RESULTS
G9a associates with and enhances Sharp-1–mediated 
transcriptional repression
We previously demonstrated that Sharp-1 overexpression in preadi-
pocytes inhibits their differentiation into adipocytes. Concomitantly, 
G9a and its hallmark repressive chromatin mark H3K9me2 were ap-
parent on adipogenic promoters, suggesting that Sharp-1 may re-
cruit G9a to inhibit cellular differentiation programs (Gulbagci et al., 
2009). Indeed our recent studies showed that similar to Sharp-1, 
G9a overexpression in myoblasts impairs skeletal muscle differentia-
tion (Azmi et al., 2004; Ling et al., 2012). To examine whether G9a is 
a corepressor involved in Sharp-1–dependent inhibition of skeletal 
myogenesis, we first investigated whether the two proteins interact 
by coimmunoprecipitation assays. Sharp-1 was expressed with full-
length G9a or a deletion mutant lacking the ankyrin repeats 
(G9a∆ANK). Immunoprecipitation of Sharp-1 revealed that it inter-
acts with G9a but not with G9a∆ANK, indicating that the ankyrin 
repeats are essential for association (Figure 1A). To identify the 
domain(s) in Sharp-1 needed for association, we transfected cells 
with Sharp-1 and its deletion mutants along with G9a (Figure 1B). 
Sharp-1 interacted with G9a through a region spanning amino acid 
residues 173–265 (Figure 1B), which was previously shown to be 
important for transcriptional repression (Garriga-Canut et al., 2001). 
Sharp-1 and G9a colocalization in the nucleus was apparent in 
C2C12 myoblasts, as well as in C3H10T1/2 (10T1/2) and NIH3T3 fi-
broblast cells (Figure 1C and unpublished data). Moreover, in gluta-
thione S-transferase (GST) pull-down assays, G9a interacted with 
GST–Sharp-1 but not with GST, confirming a direct interaction be-
tween the two proteins (Figure 1D). We then tested whether G9a is 
involved in Sharp-1–mediated transcriptional repression. We trans-
fected 10T1/2 fibroblast cells with 6E-TATA-Luc harboring Sharp-1–
binding sites (Rossner et al., 2008). Coexpression of G9a enhanced 
transcriptional repression by Sharp-1 (Figure 1E), and, conversely, 
inhibition of G9a activity with BIX-01294 (Kubicek et al., 2007) or 
UNC0638 (Vedadi et al., 2011) reversed it (Figure 1, F and G). To 
investigate whether G9a contributes to Sharp-1–mediated repres-
sion of myogenesis, we analyzed its impact on the myogenin 
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FIGURE 1: G9a interacts with and enhances Sharp-1–mediated transcriptional repression. (A) Schematic representation of 
full-length G9a and a deletion mutant lacking the ankyrin repeats (G9a∆ANK). Numbers indicate amino acid residues. Cells 
transfected with Myc–Sharp-1, FLAG-G9a, and FLAG-G9a∆ANK were immunoprecipitated with anti–c-Myc agarose beads 
and immunoblotted with anti-FLAG antibody. Lysates were analyzed for Sharp-1 and G9a expression by Western blot. 
β-Actin was used as a loading control. (B) Schematic representation of Sharp-1 with basic (b), helix-loop-helix (HLH), and 
Orange (O) domains. Deletion mutants of Sharp-1 are shown. Sharp-1 was immunoprecipitated and analyzed for interaction 
with G9a using anti-FLAG antibody. (C) Colocalization of Myc–Sharp-1(green) and FLAG-G9a (red) was visualized by 
immunofluorescence in C2C12 and 10T1/2 cells. Nuclei were stained with DAPI (blue). (D) In vitro–translated G9a was used 
for interaction with equivalent amounts of GST–Sharp-1 and GST proteins. A 10% input was run as a control. (E–G) 10T1/2 
cells were transfected with 6E-TATA-Luc along with Sharp-1 and G9a (E), with Myc-Sharp-1 and 2.5 μM of BIX-01294 (F), or 
with 0.25 μM UNC0638 (G). (H, I) Cells were transfected with pMyog-Luc, MyoD, Sharp-1, and G9a (H) and, in the presence 
of MyoD, Sharp-1 with 2.5 μM BIX-01294 or 0.25 μM UNC0638 (I). Error bars indicate mean ± SD. (J) Cells were transfected 
with pMyogLuc along with Sharp-1 and deletion mutants together with G9a and G9a∆ANK. Error bars indicate mean ± SD. 
(K) Mouse embryo sections were immunostained with anti-G9a antibody at E12, E14, and E16. Arrowheads in magnified 
images indicate G9a expression (brown staining) in diaphragm, tongue, and limb muscles. Negative control shows E12 
embryo section stained with secondary antibody only. A magnified image of the diaphragm is shown. Scale bar, 100 μm.
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FIGURE 2: Sharp-1 inhibits differentiation with increased H3K9me2. (A) Sharp-1 expression in pBabe (control) and 
pBabe-Sharp-1 C2C12 cells was analyzed by Western blot. (B–D) Differentiation of control and pBabe-Sharp-1 cells was 
analyzed with anti-MHC antibody. Nuclei were stained with DAPI (B). The myogenic index was determined and is 
represented as mean ± SD (C). Lysates from undifferentiated myoblasts (day 0) and after differentiation (days 1 and 3) 
were examined for myogenin and troponin T (D). (E, F) ChIP assays were performed at days 0 and 2 on the myogenin 
promoter, using H3K9me2 and H3K9K14ac antibodies. (G) C2C12 cells were transfected with scrambled siRNA or 
Sharp-1 siRNA (siSharp-1). The down-regulation of endogenous Sharp-1 was analyzed by Western blot. 
(H–J) Differentiation in siRNA and siSharp-1 cells was quantified by immunofluorescence analysis of MHC+ myotubes (H), 
myogenic index (I), and expression of myogenin and troponin T (J). (K) H3K9me2 enrichment was analyzed by ChIP in 
siRNA and siSharp-1 cells in undifferentiated (day 0) and differentiated cells (day 2).
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FIGURE 3: Inhibition of G9a rescues Sharp-1–imposed differentiation block. (A) C2C12 cells overexpressing Sharp-1 
were transfected with control siRNA or siG9a. G9a knockdown was determined by Western blot. (B) Cells were induced 
to differentiate and stained with anti-MHC antibody. Nuclei were stained with DAPI. (C) Differentiation was quantified 
by calculating myogenic index. (D) Myogenin and troponin T expression was determined by Western blot. 
(E–G) Sharp-1–overexpressing cells were incubated with DMSO (vehicle) or BIX-01294. Differentiation was assessed 
using anti-MHC antibody (E), myogenic index (F), and expression of myogenin and troponin T by Western blot (G). 
(H) Sharp-1–overexpressing cells were treated with DMSO or BIX-01294 for 0 and 2 d. ChIP assays were done using 
anti-H3K9me2 antibody on the myogenin promoter. (I) C2C12 cells were transfected with Myc–Sharp-1 and MyoD. 
MyoD was immunoprecipitated and analyzed for association with G9a and methylation in the absence and presence of 
UNC0638 treatment using anti-G9a and anti-Me Lys antibodies, respectively. Lysates were analyzed for expression of 
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pared with control cells (Figure 3K). Taken together, these results 
suggest that Sharp-1 enhances both H3K9me2 and MyoD methyla-
tion likely via recruitment of G9a. We previously showed that Sharp-1 
inhibits DNA-binding activity of MyoD (Azmi et al., 2004). To test 
whether G9a participates in inhibition of MyoD binding, we exam-
ined MyoD occupancy at the myogenin promoter in Sharp-1– and 
G9a–overexpressing cells. Consistent with our previous observa-
tions (Azmi et al., 2004), MyoD binding was reduced in Sharp-1–
overexpressing cells but not in G9a-overexpressing cells (Figure 3L). 
These results suggest that Sharp-1–mediated displacement of 
MyoD occupancy occurs independent of G9a recruitment.
To investigate the significance of G9a-mediated H3K9me2 and 
MyoD methylation in Sharp-1–dependent repression of myogene-
sis, we reexpressed wild-type MyoD and MyoD(K104R) (Sartorelli 
et al., 1999) in Sharp-1–overexpressing C2C12 cells (Figure 4A). 
Sharp-1 increased H3K9me2, we examined its impact on MyoD 
methylation, which is also mediated by G9a (Ling et al., 2012). 
C2C12 cells transfected with Sharp-1 and MyoD were left untreated 
or treated with UNC0638. Immunoprecipitation of MyoD revealed 
its association with endogenous G9a and was correspondingly 
methylated. Coexpression of Sharp-1 enhanced MyoD-G9a associa-
tion and MyoD methylation. In the presence of UNC0638, MyoD 
methylation was reduced, without any impact on the MyoD–G9a 
complex (Figure 3I). Because both MyoD and Sharp-1 interact with 
the ankyrin-repeat domain in G9a, we tested whether MyoD had an 
impact on G9a–Sharp-1 association. In the presence of MyoD, the 
association of Sharp-1 and G9a was increased, indicating that both 
Sharp-1 and MyoD enhance association of all three proteins in a 
larger complex (Figure 3J). Consistent with this, MyoD–G9a interac-
tion and MyoD methylation were reduced in siSharp-1 cells com-
FIGURE 4: MyoD methylation is relevant in the inhibition of myogenesis by Sharp-1. (A) C2C12 cells overexpressing 
Sharp-1 were transfected with MyoD and MyoD(K104R). MyoD expression was analyzed by Western blot. (B-D) Control 
(vector), MyoD, and MyoD(K104R) cells were analyzed for differentiation with anti-MHC antibody (B), myogenic index 
(C), and troponin T expression by Western blot (D). (E) C3H10T1/2 cells were transfected with MyoD, MyoD(K104R), 
Myc-Sharp-1, and FLAG-G9a. MyoD was immunoprecipitated and probed with anti-Me Lys antibody. Expression of 
Sharp-1, MyoD, and G9a was analyzed in lysates. (F) ChIP assays were performed in Sharp-1–overexpressing C2C12 
cells transfected with MyoD and MyoD(K104R). H3K9me2 was analyzed by ChIP assays on the myogenin promoter at 
D2 of differentiation. Error bars indicate mean ± SD.
G9a, MyoD, and Sharp-1. (J) C2C12 cells were transfected with Myc–Sharp-1 and MyoD and G9a as indicated. The 
association of Sharp-1 with G9a was analyzed in the absence and presence of MyoD. (K) Endogenous MyoD methylation 
and association with G9a was examined by immunoprecipitation from siSharp-1 and siRNA cells using anti-Me Lys and 
anti-G9a antibodies. Input shows expression of G9a, Sharp-1, and MyoD in lysates. (L) MyoD occupancy on the 
myogenin promoter was analyzed by ChIP assays in myoblasts overexpressing pBabe, Sharp-1, or G9a. Error bars 
indicate mean ± SD.
4784 | B. M. T. Ling et al. Molecular Biology of the Cell
methylation, which appears to be critical in the differentiation block 
imposed by Sharp-1. 5) Sharp-1–bHLH mutant, which fails to inter-
act with G9a, represses MyoD to a lesser extent (∼50% inhibition) 
than full-length Sharp-1 (∼75% inhibition). The inhibition of MyoD by 
Sharp-1–bHLH is likely a reflection of heterodimerization with MyoD 
and E-proteins through the HLH domain, which may account for loss 
of MyoD DNA binding and can occur independent of G9a recruit-
ment. On the other hand, recruitment of G9a results in H3K9me2 
and MyoD methylation, resulting in loss of MyoD transcriptional ac-
tivity independent of effects on MyoD DNA binding.
In addition to Sharp-1, G9a has been documented to interact 
with various transcription factors, including Snail, Gfi1, NF-kB, 
CDP, and REST (Nishio and Walsh, 2004; Roopra et al., 2004; Duan 
et al., 2005; Chen et al., 2009; Dong et al., 2012), which recruit it 
to distinct target promoters. Given its recruitment in muscle cells, 
targeting G9a may be therapeutically useful in myopathies with 
elevated Sharp-1 expression.
MATERIALS AND METHODS
Cell culture and differentiation assays
C2C12 cells were cultured in DMEM supplemented with 20% fetal 
bovine serum (FBS) and differentiated in DMEM supplemented 
with 2% horse serum. Phoenix, HEK293, and C3H10T1/2 cells 
were cultured in DMEM supplemented with 10% FBS. Differentia-
tion in C2C12 cells was quantified by determining the ratio of nu-
clei in MHC+ myotubes over total nuclei (myogenic index). At least 
600 nuclei were counted from three different fields.
Retroviral transduction and siRNA
C2C12 cells were transduced with pBabe (vector) or pBabe-Sharp-1 
and selected with 2 μg/ml puromycin. pBabe-Sharp-1 cells were 
transfected with 100 nM scrambled siRNA or siG9a as described 
(Ling et al., 2012). For knockdown of Sharp-1, C2C12 cells were 
transfected with 100 nM Sharp-1 siRNA (Qiagen, Valencia, CA). G9a 
inhibitors BIX-01294 and UNC0638 (Sigma-Aldrich, St. Louis, MO) 
were used at 2.5 and 0.25 μM, respectively. Control cells were 
treated with dimethyl sulfoxide (vehicle).
Plasmids
FLAG-G9a, FLAG-G9a∆ANK, FLAG-MyoD, FLAG-MyoD(K104R), 
GST-Sharp-1, 6E-TATA, pMyogLuc, Myc-Sharp-1, and Myc-Sharp-1-
bHLH have been described (Sartorelli et al., 1999; Friday et al., 
2000; Azmi et al., 2004; Rossner et al., 2008; Gulbagci et al., 2009; 
Ling et al., 2012). Myc-Sharp-1∆O (∆ orange domain) and Myc-
Sharp-1∆C (amino acids 1–265) were generated by PCR. Primer 
sequences are available upon request.
Immunoprecipitation and Western blot
A 500-μg amount of lysate was incubated with c-Myc agarose 
beads (Sigma-Aldrich) or 2 μg of anti-MyoD (Sigma-Aldrich) 
and analyzed by Western blot. The following antibodies were 
used: anti-MyoD and anti-myogenin (Santa Cruz Biotechnology, 
Santa Cruz, CA); anti-troponin T, anti-FLAG, anti-Myc, anti–Sharp-1, 
and anti–β-actin (Sigma-Aldrich); anti-G9a/EHMT2 (Cell Signaling, 
Beverly, MA) and anti-Me Lys (Abcam, Cambridge, MA).
GST pull-down assay
Glutathione–Sepharose beads were incubated with 10 μg of GST or 
GST-Sharp-1 and 20 μl of in vitro–translated FLAG-G9a prepared 
using TNT-coupled reticulocyte lysate system (Promega, Madison, 
WI). Eluted proteins were analyzed by Western blot using anti-Flag 
antibody.
Consistent with our previous studies (Azmi et al., 2004), reexpres-
sion of MyoD partially rescued myogenic differentiation and tro-
ponin T expression (Figure 4, B–D). Of interest, at equivalent levels 
of expression, MyoD(K104R) was more effective in rescuing differen-
tiation compared with wild-type MyoD. To examine the mechanisms 
underlying this effect, we examined the impact of Sharp-1 and G9a 
on MyoD and MyoD(K104R) (Figure 4E). In contrast to wild-type 
MyoD, the methylation of which was augmented in the presence of 
G9a alone and together with Sharp-1, MyoD(K104R) was insensitive 
to both proteins. The level of H3K9me2 was not altered by MyoD 
and MyoD(K104R) (Figure 4F), indicating that MyoD methylation 
plays a key role in the inhibition of myogenesis by Sharp-1.
DISCUSSION
In this study we provide novel insights that link Sharp-1 to epige-
netic mechanisms for inhibition of skeletal muscle differentiation via 
recruitment of the corepressor G9a. We provide evidence that G9a 
is expressed in vivo in developing skeletal muscles. G9a interacts 
with and enhances Sharp-1–dependent repression of MyoD activity 
and target gene expression in a methyltransferase activity–depen-
dent manner. In the absence of G9a function, both MyoD repression 
and the differentiation block imposed by Sharp-1 are rescued.
Sharp-1 is a member of the bHLH-Orange subfamily of transcrip-
tion factors (Sun et al., 2007), which includes the Hes, Hey, Helt, and 
Stra13/Dec1 subfamilies. Sharp-1 binds with high affinity to E-box 
sites and also mediates repression by protein–protein interaction 
with various transcription factors, including MyoD and C/EBPβ 
(Garriga-Canut et al., 2001; Azmi et al., 2004; Fujimoto et al., 
2007; Gulbagci et al., 2009). Moreover, Sharp-1 interacts with the 
corepressors HDAC1 and Sirt1 (Garriga-Canut et al., 2001; Fujimoto 
et al., 2007). However, the functional significance of association with 
these cofactors in Sharp-1–mediated biological functions in cellular 
differentiation, growth arrest, tumor cell quiescence, or circadian 
rhythms have not been documented.
We and others showed that Sharp-1 interacts with MyoD and 
inhibits its transcriptional activity and myogenic differentiation (Azmi 
et al., 2004; Fujimoto et al., 2007). The repression of MyoD and 
muscle differentiation by Sharp-1 likely involve multiple repression 
mechanisms. This includes formation of inactive heterodimers with 
MyoD and E-proteins that likely result in the inhibition of MyoD 
DNA binding. However, Sharp-1 inhibits tethered MyoD∼E47 het-
erodimers (Azmi et al., 2004), suggesting that additional mecha-
nisms must be involved. Several lines of evidence in this study dem-
onstrate that Sharp-1–dependent inhibition of MyoD and myogenesis 
is at least in part dependent on association with G9a and its recruit-
ment at muscle promoters. 1) Sharp-1–overexpressing cells exhibit 
elevated G9a-mediated H3K9me2, which correlates with reduced 
myogenin expression and impaired muscle differentiation. Con-
versely, inhibition of endogenous Sharp-1 expression accelerates 
differentiation and is linked to reduced H3K9me2 at the myogenin 
promoter. 2) Reduction of G9a expression or pharmacological inhi-
bition of its activity abrogates Sharp-1–dependent inhibition of dif-
ferentiation concomitant with reduction of H3K9 and MyoD methy-
lation. 3) G9a augments Sharp-1–dependent repression of MyoD 
activity at the myogenin promoter and, conversely, inhibition of its 
activity blocks it. Moreover, G9a∆ANK fails to associate with Sharp-1 
and does not affect Sharp-1–dependent repression of myogenin. 
4) The association of G9a with MyoD is enhanced in presence of 
Sharp-1 (Figure 3). This suggests that Sharp-1 could serve as an 
adaptor protein linking G9a to MyoD, thereby influencing MyoD 
transcriptional activity through epigenetic regulation of target 
genes. Consistently, Sharp-1 increases G9a-dependent MyoD 
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Immunofluorescence analysis
Cells were incubated with anti-MHC (MY32), anti–Sharp-1, and 
anti–c-Myc (Sigma-Aldrich) antibodies, followed by Alexa Fluor 
488 or with Alexa Fluor 568 antibodies (Molecular Probe, Eugene, 
OR). Nuclei were stained with 4′,6-diamidino-2-phenylindole 
(DAPI; Vector Laboratories, Burlingame, CA). Images were cap-
tured using a fluorescence microscope (Nikon Eclipse TE 2000-U; 
Nikon, Melville, NY) at 10× or 20× magnification using MetaMorph 
software, version 7.0r3 (Molecular Devices, Sunnyvale, CA).
Immunostaining of mouse embryo sections
Sagittal mouse embryo cryosections (Zyagen, San Diego, CA) were 
incubated with anti-G9a antibody, followed by detection with 
Vectastain ABC Kit (Vector Laboratories). Negative controls were 
performed by incubation with secondary antibody only. Slides were 
mounted using DePeX (Sigma-Aldrich) mounting media, and 
peroxidase staining was visualized under an Olympus slide scanner 
(Olympus, Tokyo, Japan) and photographed using an Aperio image 
scope viewer (Aperio, Vista, CA).
Luciferase assays
Cells were transfected with pMyog-Luc or 6E-TATA reporters with 
Myc–Sharp-1, FLAG-G9a, or FLAG-MyoD as indicated in the figure 
legends and 5 ng of Renilla luciferase. Luciferase activity was mea-
sured using the dual-luciferase reporter assay system (Promega). 
Experiments were performed at least twice, in triplicate.
Chromatin immunoprecipitation assay
ChIP assays were performed in C2C12 cells using 2 μg of H3K9me2 
(Millipore, Billerica, MA), H3K9K14ac (Millipore), or MyoD (Santa 
Cruz Biotechnology) antibodies using the ChIP assay kit (Upstate, 
Millipore). DNA was amplified with primers specific to myogenin 
and β-actin promoters as described (Ling et al., 2012)
Statistical analysis
The p values were determined using Student’s t test and presented 
as mean ± SD (*p < 0.05, **p < 0.01, ***p < 0.001).
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